At the expo, French drugmaker Sanofi exhibited its ecosystem, as well as its latest products for conditions such as immunological, cardiovascular, metabolic and other diseases.

　　Local R&D plays a key role in Sanofi's development. Sanofi now operates R&D centers in cities such as Beijing and Shanghai, and its Chinese research staff have been deeply involved in over 90 percent of its global co-development projects, including 12 potential blockbuster drugs.

　　For Sanofi, the supply chain expo serves as a platform not only to showcase its products but also to build collaborations.

　　“Here, we explore innovative collaborations with our global partners, from R&D to production and patient accessibility enhancement, and share the latest results of localized practices,“ said Wayne Shi, president of Sanofi Greater China. Sanofi will continue to support the Healthy China initiative with innovative drugs and vaccines, Shi said.

　　Meanwhile, Novo Nordisk announced new partnerships with local manufacturing, logistics and tech firms at the expo, as part of its latest efforts to deepen local industrial chain cooperation.

　　Novo Nordisk has continued to increase its investment in China, enhancing its presence throughout the industry chain to better serve patients in China. To date, the company has introduced 22 innovative drugs and 11 innovative injection devices in China for the treatment of diabetes, obesity and rare diseases.

　　As a participant in all three editions of the supply chain expo, Novo Nordisk is joining more industrial chain partners this year to build a comprehensive health management ecosystem that drives chronic disease management, said Christine Zhou, president of Novo Nordisk Region China.